Sativex faces more delays

The UK's GW Pharma has taken two blows in one day. In a report filed by Agence de Presse Medical, an unnamed regulator said that the biotech had failed in its bid to persuade British regulators to let it go ahead and market the cannabis-based Sativex without further trials. Its stock also went into a tailspin after the US Supreme Court ruled Monday that state laws did not protect marijuana smokers from federal laws banning the substance. GW Pharma had hoped to start selling Sativex in the UK by the end of 2003 but has faced repeated delays in getting it to market.

- read this story from Sharecast

ALSO: Critics contend that it is inconsistent for the Supreme Court to rule that it is legal for doctors to advise patients on using marijuana and then decide that state laws don't protect users. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.